NanoPass Technologies, an Israeli company that develops solutions for painless delivery of vaccines and drugs, has teamed up with Micro2Nano in South Korea to develop and produce the company’s innovative products.
The aim of the collaboration is to strengthen the relationship between NanoPass and M2N and provide a basis for the continued growth of the two companies while basing the new agreement on years of development and production collaboration.
NanoPass’s microneedle device is based on MEMS (micro-electro-mechanical systems) technology and is made of pure silicon crystal. According to the company, silicon crystal is one of the Earth’s pure chemical elements and is known for its robustness and biocompatibility.
Less than 1 mm. in size, the microneedle is easy to use and is practically painless when delivering vaccines or other therapeutics. It can be used with any standard syringe to inject liquid substances directly into the skin.
“M2N has been a trusted partner for over a decade and has been assisting NanoPass regularly with both its development projects and ongoing commercial production,” NanoPass CEO Yotam Levin said in a press release. “For us, trust is a key parameter for any partner, and M2N’s organizational culture provides just the thing.”
Micro2Nano CEO Kyuho Hwang said the company “is excited to provide high-quality microneedles to NanoPass as a prime manufacturer and to support NanoPass in developing the new business applications as a strategic R&D partner.”